Methods for treating adrenal gland tumors

A method of reducing the tumor load of an adrenal gland tumor in a patient suffering from said adrenal gland tumor, wherein said reducing the tumor load comprises one or more of reducing the size of, reducing a dimension of, reducing the volume of, reducing the mass of, reducing the weight of, causing degenerative changes in, inducing apoptosis in at least part of, preventing the growth of, slowing the growth of, reducing secretion from, and altering the composition of hormones secreted from one or more adrenal gland tumor(s) in said patient,

• the method comprising administering an effective amount of a glucocorticoid receptor modulator (GRM) to the patient, wherein the GRM comprises a heteroaryl-ketone fused azadecalin structure of formula (I),
• wherein
• R1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R1a,
• each R1a is independently selected from the group consisting of hydrogen, C1-6 alkyl, halogen, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, —CN, N-oxide, C3-8 cycloalkyl, and C3-8 heterocycloalkyl;
• ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S;
• each R2 is independently selected from the group consisting of hydrogen, C1-6 alkyl, halogen, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl-C1-6 alkoxy, —CN, —OH, —NR2aR2b, —C(O)R2a, —C(O)OR2a, —C(O)NR2aR2b, —SR2a, —S(O)R2a, —S(O)2R2a, C3-8 cycloalkyl, and C3-8 heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 R2c groups;
• alternatively, two R2 groups linked to the same carbon are combined to form an oxo group (═O);
• alternatively, two R2 groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R2d groups;
• R2a and R2b are each independently selected from the group consisting of hydrogen and C1-6 alkyl;
• each R2c is independently selected from the group consisting of hydrogen, halogen, hydroxy, C1-6 alkoxy, C1-6 haloalkoxy, —CN, and —NR2aR2b;
• each R2d is independently selected from the group consisting of hydrogen and C1-6 alkyl, or two R2d groups attached to the same ring atom are combined to form (═O);
• R3 is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 R3a groups;
• each R3a is independently selected from the group consisting of hydrogen, halogen, and C1-6 haloalkyl;
• subscript n is an integer from 0 to 3;
• or salts and isomers thereof,
• effective to reduce the tumor load of adrenal gland tumor(s) in a patient suffering therefrom.